RAPT Therapeutics announced that it has initiated its global 14-week randomized, double-blind, placebo-controlled Phase 2a clinical trial to evaluate the efficacy and safety of RPT193 as an oral, once-daily monotherapy in patients with moderate-to-severe asthma. "We are excited by the potential of RPT193 as a well-tolerated, once-daily, oral treatment for patients with asthma," said Brian Wong, M.D., Ph.D., President and CEO of RAPT. "Following promising results from our Phase 1b trial in atopic dermatitis, where RPT193 demonstrated clinically meaningful improvement in signs and symptoms of the disease, we see asthma as the next pillar in our pipeline-in-a-product strategy. We look forward to generating proof-of-concept in this indication."
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on RAPT:
- Cantor biopharma/biotech analysts hold analyst/industry conference call
- Biotech Alert: Searches spiking for these stocks today
- Rapt outlook ‘remains steady’ despite shift in timeline, says Capital One
- Rapt Therapeutics price target lowered to $40 from $44 at Cantor Fitzgerald
- Rapt Therapeutics price target lowered to $43 from $50 at H.C. Wainwright
